Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2010 (2010), Article ID 395720, 4 pages
http://dx.doi.org/10.1155/2010/395720
Case Report

Metronomic Treatment with Low-Dose Trofosfamide Leads to a Long-Term Remission in a Patient with Docetaxel-Refractory Advanced Metastatic Prostate Cancer

1Department of Internal Medicine III, University of Ulm, Albert Einstein-Allee 23, 89081 Ulm, Germany
2Department of Urology, University of Ulm, Robert-Koch-Str. 8, 89081 Ulm, Germany
3Department of Nuclear Medicine, University of Ulm, Robert-Koch-Str. 8, 89081 Ulm, Germany
4Internal Medicine, Clinic of Dinkelsbühl, Germany
5IIIrd Department of Medicine, Clinic of Karlsruhe, 76133 Karlsruhe, Germany

Received 23 June 2009; Revised 25 February 2010; Accepted 15 March 2010

Academic Editor: Jonathan Melamed

Copyright © 2010 Jochen Greiner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Hanahan, G. Bergers, and E. Bergsland, “Less is, more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice,” Journal of Clinical Investigation, vol. 105, no. 8, pp. 1045–1047, 2000. View at Google Scholar · View at Scopus
  2. R. Samaritani, G. Corrado, E. Vizza, and C. Sbiroli, “Cyclophosphamide “metronomic” chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer,” BMC Cancer, vol. 7, article 65, 2007. View at Publisher · View at Google Scholar · View at PubMed
  3. H.-G. Kopp, L. Kanz, and J. T. Hartmann, “Complete remission of relapsing high-grade angiosarcoma with single-agent metronomic trofosfamide,” Anti-Cancer Drugs, vol. 17, no. 8, pp. 997–998, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. I. F. Tannock, R. de Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. J. E. Rosenberg, V. K. Weinberg, W. K. Kelly et al., “Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone,” Cancer, vol. 110, no. 3, pp. 556–563, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. B. V. Offersen, M. Borre, and J. Overgaard, “Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density,” European Journal of Cancer, vol. 39, no. 7, pp. 881–890, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Weidner, P. R. Carroll, J. Flax, W. Blumenfeld, and J. Folkman, “Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma,” American Journal of Pathology, vol. 143, no. 2, pp. 401–409, 1993. View at Google Scholar · View at Scopus
  8. W. N. Brennen, C. R. Cooper, S. Capitosti, M. L. Brown, and R. A. Sikes, “Thalidomide and analogues: current proposed mechanisms and therapeutic usage,” Clinical Prostate Cancer, vol. 3, no. 1, pp. 54–61, 2004. View at Google Scholar · View at Scopus
  9. E. K. Salminen, J. Sundstrom, and V. Nikkanen, “Palliative chemotherapy with trofosfamide in advanced prostate cancer,” Anticancer Research, vol. 26, no. 1, pp. 539–542, 2006. View at Google Scholar · View at Scopus
  10. S. Stoelting, T. Trefzer, J. Kisro, A. Steinke, T. Wagner, and S. O. Peters, “Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients,” In Vivo, vol. 22, no. 6, pp. 831–836, 2008. View at Google Scholar · View at Scopus
  11. J. B. Aragon-Ching, Y.-M. Ning, C. C. Chen et al., “Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents,” Cancer Investigation, vol. 27, no. 2, pp. 221–226, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus